DrugPatentWatch Database Preview
KERYDIN Drug Profile
When do Kerydin patents expire, and what generic alternatives are available?
Kerydin is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has seventy-seven patent family members in twenty-one countries.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tavaborole profile page.
Summary for KERYDIN
| International Patents: | 77 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 67 |
| Clinical Trials: | 1 |
| Patent Applications: | 64 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for KERYDIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KERYDIN |
| DailyMed Link: | KERYDIN at DailyMed |
Generic Entry Opportunity Date for KERYDIN
Generic Entry Date for KERYDIN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for KERYDIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | Phase 4 |
Recent Litigation for KERYDIN
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Anacor Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. | 2018-10-29 |
| Anacor Pharmaceuticals, Inc. v. Lupin Limited | 2018-10-17 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Mylan Pharmaceuticals Inc. | 2018-07-10 |
| Mylan Pharmaceuticals Inc. | 2018-07-06 |
| FlatWing Pharmaceuticals, LLC | 2017-11-21 |
Pharmacology for KERYDIN
| Drug Class | Oxaborole Antifungal |
| Mechanism of Action | Protein Synthesis Inhibitors |
Synonyms for KERYDIN
| 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole |
| 174671-46-6 |
| 2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy- |
| 3338AH |
| 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole |
| 5-Fluoro-1-hydroxyl-1,3-dihydrobenzo[c][1,2]oxaborole |
| 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole |
| 5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol |
| 5-fluoro-2,1-benzoxaborol-1(3H)-ol |
| 5-Fluoro-3H-benzo[c][1,2)oxaborol-1-ol |
| 5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol |
| 5-FLUOROBENZO[C][1,2]OXABOROL-1(3H)-OL |
| AK163946 |
| AKOS006303927 |
| AN 2690 |
| AN-2690 |
| AN-2690(Tavaborole) |
| AN2690 |
| BCP08730 |
| BDBM50370987 |
| C7H6BFO2 |
| CHEBI:77942 |
| CHEMBL443052 |
| CS-1058 |
| CTK8H2675 |
| D10169 |
| DB09041 |
| DS-8392 |
| DTXSID00169888 |
| EX-A1086 |
| FT-0697827 |
| HSDB 8342 |
| HY-10980 |
| K124A4EUQ3 |
| KB-74687 |
| Kerydin (TN) |
| KS-00000SPV |
| LFQDNHWZDQTITF-UHFFFAOYSA-N |
| MB08883 |
| MFCD10699483 (95%) |
| MolPort-027-845-281 |
| NCGC00264110-01 |
| SCH-900340 |
| SCHEMBL500016 |
| ST24044751 |
| SY038332 |
| Tavaborole |
| Tavaborole (USAN) |
| Tavaborole [USAN:INN] |
| UNII-K124A4EUQ3 |
| W-5454 |
| X3699 |
| Z1739256284 |
| ZINC169990691 |
US Patents and Regulatory Information for KERYDIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for KERYDIN
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 5% | ➤ Subscribe | See Pricing |
International Patents for KERYDIN
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200707408 | See Pricing |
| European Patent Office | 1853251 | See Pricing |
| Japan | 5038912 | See Pricing |
| Hong Kong | 1160139 | See Pricing |
| South Korea | 101337045 | See Pricing |
| South Korea | 20070112390 | See Pricing |
| Canada | 2635680 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
